The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication

Journal of Virology

Volumn 86, Issue 7, 2012, Pages 3777-3786

  Wang, Xiaoxia ^a   Ao, Zhujun ^a   Chen, Liyu ^a,b   Kobinger, Gary ^a   Peng, Jinyu ^a   Yao, Xiaojian ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS; GENE DISRUPTION; GENE MAPPING; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; ULTRACENTRIFUGATION; VIRION; VIRUS REPLICATION;

AMINO ACID MOTIFS; CELL LINE; CYTIDINE DEAMINASE; DOWN-REGULATION; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PROTEIN BINDING; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84861313985     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06594-11     Document Type: Article

References (65)

1. Alce TM, Popik W. 2004. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J. Biol. Chem. 279: 34083-34086.
2. Anderson J, Akkina R. 2005. TRIM5alpharh expression restricts HIV-1 infection in lentiviral vector-transduced CD34+-cell-derived macrophages. Mol. Ther. 12: 687-696.
3. Andreola ML. 2009. Therapeutic potential of peptide motifs against HIV-1 reverse transcriptase and integrase. Curr. Pharm. Des. 15: 08-2519.
4. Ao Z, et al. 2010. Importin alpha3 interacts with HIV-1 integrase and contributes to HIV-1 nuclear import and replication. J. Virol. 84: 8650-8663.
5. Ao Z, Fowke KR, Cohen EA, Yao X. 2005. Contribution of the C-terminal tri-lysine regions of human immunodeficiency virus type 1 integrase for efficient reverse transcription and viral DNA nuclear import. Retrovirology 2: 62.
6. Ao Z, et al. 2007. Interaction of human immunodeficiency virus type 1 integrase with cellular nuclear import receptor importin 7 and its impact on viral replication. J. Biol. Chem. 282: 13456-13467.
7. Ao Z, Yao X, Cohen EA. 2004. Assessment of the role of the central DNA flap in human immunodeficiency virus type 1 replication by using a single-cycle replication system. J. Virol. 78: 3170-3177.
8. Ao Z, Yu Z, Wang L, Zheng Y, Yao X. 2008. Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection. PLoS One 3: e1995.
9. Bishop KN, Holmes RK, Malim MH. 2006. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J. Virol. 80: 8450-8458.
10. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. 2008. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 4: e1000231.
11. Cancio R, Spadari S, Maga G. 2004. Vif is an auxiliary factor of the HIV-1 reverse transcriptase and facilitates abasic site bypass. Biochem. J. 383: 475-482.
12. Casartelli N, et al. 2010. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. J. Exp. Med. 207: 39-49.
13. Cen S, et al. 2004. The interaction between HIV-1 Gag and APOBEC3G. J. Biol. Chem. 279: 33177-33184.
14. Coker HA, Petersen-Mahrt SK. 2007. The nuclear DNA deaminase AID functions distributively whereas cytoplasmic APOBEC3G has a processive mode of action. DNA Repair 6: 235-243.
15. Douaisi M, et al. 2004. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem. Biophys. Res. Commun. 321: 566-573.
16. Druillennec S, et al. 1999. A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity. Proc. Natl. Acad. Sci. U. S. A. 96: 4886-4891.
17. Esnault C, et al. 2005. APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses. Nature 433: 430-433.
18. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L. 2006. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J. Virol. 80: 11710-11722.
19. Lys annealing to viral RNA. J. Virol. 81: 11322-11331.
20. Lys annealing to viral RNA in human immunodeficiency virus type 1. J. Virol. 83: 8099-8107.
21. Harris RS, et al. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113: 803-809.
22. Hehl EA, Joshi P, Kalpana GV, Prasad VR. 2004. Interaction between human immunodeficiency virus type 1 reverse transcriptase and integrase proteins. J. Virol. 78: 5056-5067.
23. Herschhorn A, Hizi A. 2010. Retroviral reverse transcriptases. Cell. Mol. Life Sci. 67: 2717-2747.
24. Holmes RK, Koning FA, Bishop KN, Malim MH. 2007. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation: comparisons with APOBEC3G. J. Biol. Chem. 282: 2587-2595.
25. Huthoff H, Malim MH. 2007. Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation. J. Virol. 81: 07-3815.
26. Iwatani Y, et al. 2007. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res. 35: 7096-7108.
27. Jacobo-Molina A, Arnold E. 1991. HIV reverse transcriptase structurefunction relationships. Biochemistry 30: 6351-6356.
28. Jarmuz A, et al. 2002. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 79: 5-296.
29. Kataropoulou A, et al. 2009. Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res. 37: 3660-3669.
30. Khan MA, et al. 2005. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J. Virol. 79: 70-5874.
31. Laguette N, et al. 2011. SAMHD1 is the dendritic- and myeloid-cellspecific HIV-1 restriction factor counteracted by Vpx. Nature 474: 654-657.
32. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300: 1112.
33. Levin JG, Mitra M, Mascarenhas A, Musier-Forsyth K. 2010. Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription. RNA Biol. 7: 754-774.
34. Li XY, Guo F, Zhang L, Kleiman L, Cen S. 2007. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. J. Biol. Chem. 282: 32065-32074.
35. Luo K, et al. 2004. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J. Virol. 78: 11841-11852.
36. Luo K, et al. 2007. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. J. Virol. 81: 7238-7248.
37. Malim MH. 2009. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 364: 675-687.
38. Mangeat B, et al. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424: 99-103.
39. Mariani R, et al. 2003. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 114: 21-31.
40. Mbisa JL, et al. 2007. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. J. Virol. 81: 7099-7110.
41. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 5-430.
42. Newman EN, et al. 2005. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 15: 166-170.
43. Nguyen DH, Hu J. 2008. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J. Virol. 82: 6852-6861.
44. Opi S, et al. 2006. Monomeric APOBEC3G is catalytically active and has antiviral activity. J. Virol. 80: 4673-4682.
45. Petersen-Mahrt S. 2005. DNA deamination in immunity. Immunol. Rev. 203: 80-97.
46. Prasad VR, Goff SP. 1990. Structure-function studies of HIV reverse transcriptase. Ann. N. Y. Acad. Sci. 616: 11-21.
47. Restle T, Muller B, Goody RS. 1990. Dimerization of human immunodeficiency virus type 1 reverse transcriptase: a target for chemotherapeutic intervention. J. Biol. Chem. 265: 8986-8988.
48. Restle T, Muller B, Goody RS. 1992. RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett. 300: 97-100.
49. Sarafianos SG, et al. 2009. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J. Mol. Biol. 385: 693-713.
50. Sayah DM, Sokolskaja E, Berthoux L, Luban J. 2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature 430: 569-573.
51. Schafer A, Bogerd HP, Cullen BR. 2004. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 328: 163-168.
52. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418: 646-650.
53. Simon JHM, Malim MH. 1996. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 70: 5297-5305.
54. Stremlau M, et al. 2004. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427: 848-853.
55. Sunseri N, O'Brien M, Bhardwaj N, Landau NR. 2011. Human immunodeficiency virus type 1 modified to package simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells. J. Virol. 85: 6263-6274.
56. Svarovskaia ES, et al. 2004. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J. Biol. Chem. 279: 35822-35828.
57. Tisdale M, et al. 1988. Characterization of human immunodeficiency virus type 1 reverse transcriptase by using monoclonal antibodies: role of the C terminus in antibody reactivity and enzyme function. J. Virol. 62: 3662-3667.
58. Wu X, et al. 1999. Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J. Virol. 73: 2126-2135.
59. Yang Y, Guo F, Cen S, Kleiman L. 2007. Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 365: 92-100.
60. Yao XJ, et al. 1995. Degradation of CD4 induced by human immunodeficiency virus type 1 Vpu protein: a predicted alpha-helix structure in the proximal cytoplasmic region of CD4 contributes to Vpu sensitivity. Virology 209: 615-623.
61. Yao XJ, et al. 1998. Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells. J. Virol. 72: 4686-4693.
62. Yao XJ, et al. 1995. Mutagenic analysis of human immunodeficiency virus type 1 Vpr: role of a predicted N-terminal alpha-helical structure in Vpr nuclear localization and virion incorporation. J. Virol. 69: 7032-7044.
63. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD. 2004. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J. Virol. 78: 12058-12061.
64. Zhang H, et al. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424: 94-98.
65. Zheng Y, Ao Z, Wang B, Jayappa KD, Yao X. 2011. Host protein Ku70 binds and protects HIV-1 integrase from proteasomal degradation and is required for HIV replication. J. Biol. Chem. Vasanth14 286: 17722-17735.